Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2007;334:928 (5 May), doi:10.1136/bmj.334.7600.928-b
A randomised controlled trial of 1000 mg/day of chondroitin sulfate versus placebo for six months showed a minor advantage of the drug in relieving pain. This result, however, was regarded by the investigators as of questionable clinical import, with no significant difference in function over placebo. Both groups (just over 150 patients in each) with symptomatic knee osteoarthritis were permitted to take rescue medication, and no difference was seen in their use of analgesics or non-steroidal anti-inflammatory drugs. Similarly, no difference was found in relevant biochemical markers of joint metabolism, but chondroitin was rated "slightly more effective" than placebo with regard to quality of life and as an overall assessment by the investigators.